ByTrending Posts
How AbbVie Is Expanding Its Psychiatry Pipeline Through…
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Can Novartis’ 19 New Cardiovascular Studies at ESC…
Key Insights Leqvio: Can Inclisiran’s Expanding Role Become a Game-Changer in Cholesterol Management?Novartis is spotlighting the VICTORION-Difference study,…
Will MEDvidi’s AI Clinician and AI Receptionist Set…
MEDvidi, a platform for delivering remote, personalized mental health treatment, is launching AI-powered healthcare solutions for telemedicine platforms.…
Can Labcorp’s AI-Powered Test Finder Redefine Diagnostic Efficiency…
Key Highlights Expansion Into Clinical WorkflowsLabcorp (NYSE: LH) announced the integration of its AI-driven Test Finder into Labcorp…
Can Ambience Healthcare’s $243M Series C Push the…
Key Highlights Record Funding and Unicorn StatusAmbience Healthcare, founded in 2020 in San Francisco, announced a $243 million…
How Is Roche’s Expansive 2025 Pipeline and Innovative…
Key Highlights: Broad and Deep Pharmaceutical Pipeline ExpansionSince mid-2023, Roche has significantly enhanced its clinical pipeline, adding 24…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a…
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D…
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a global exclusive licensing…
Can GSK’s Gepotidacin Priority FDA Review and Strategic…
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Trending Posts
Latest Stories
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing…
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next Trillion-Dollar Neuroscience Opportunity?
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain…
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in Drug Development?
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer…
Gallery
